Agennix AG i.L.
GPC Biotech Announces Resignation of Dr. Helmut Schühsler from Supervisory Board
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
GPC Biotech Announces Resignation of Dr. Helmut Schühsler from Supervisory Board
Michael Lytton, J.D. Appointed Vice Chairman of Supervisory Board
Martinsried/Munich (Germany) and U.S. Research Facilities in Waltham/Boston,
Mass. and Princeton, N.J., November 28, 2003 – GPC Biotech AG (Frankfurt Stock
Exchange: GPC; TecDAX 30) today announced the resignation of Helmut Schühsler,
Ph.D. from the Company’s Supervisory Board, effective December 31, 2003. Dr.
Schühsler, a Managing Partner of TVM Techno Venture Management, is Vice Chairman
of the GPC Biotech Supervisory Board and has served on the Board since the
Company’s inception in 1997. Dr. Schühsler is resigning to devote more time to
his role at TVM in advising and financing early-stage, private companies.
Michael Lytton, J.D., General Partner at Oxford Bioscience Partners, who has
served on the GPC Biotech Supervisory Board since 2001, will replace Dr.
Schühsler as Vice Chairman, effective January 1, 2004. Mr. Lytton has
extensive international experience in the biotechnology field, including legal,
financial and strategic expertise.
end of ad-hoc-announcement (c)DGAP 28.11.2003
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
Bernd R. Seizinger, M.D., Ph.D., President and Chief Executive Officer of GPC
Biotech, said: “I would like to thank Dr. Schühsler for his dedication and
service to GPC Biotech through many years. He has played a pivotal role as Vice
Chairman of the Supervisory Board, and his advice and experience have been
invaluable to the Company. We are grateful that we will be able to continue to
draw on his expertise.” Dr. Seizinger continued, “We are very pleased that
Michael Lytton has agreed to accept the position of Vice Chairman. Mr. Lytton’s
vast knowledge of the biopharmaceutical field in both the U.S. and Europe has
been extremely helpful to the Company, and we look forward to his taking on a
leadership role on the Supervisory Board.”
GPC Biotech AG is a biotechnology company dedicated to discovering and
developing new anticancer drugs through innovative discovery technologies and
development approaches. The Company’s lead product candidate – satraplatin – has
recently entered a Phase 3 registrational study as a second-line chemotherapy
treatment in hormone-refractory prostate cancer, following successful completion
of a Special Protocol Assessment (SPA) by the FDA. The FDA has also granted
fast track designation to satraplatin for this indication. Other anticancer
programs in development include a monoclonal antibody with a novel mechanism-of-
action and a cell cycle inhibitor. The Company is leveraging its drug discovery
technologies in novel ways to elucidate the mechanisms-of-action of drug
candidates and to support the growth of its drug pipeline. The Company has
formed successful collaborations with a number of pharmaceutical firms,
including ALTANA Pharma of ALTANA AG (FSE: ALT; NYSE: AAA), Aventis Pharma
(PAVE.PSE), Bayer AG (FSE: BAY; NYSE: BAY), Boehringer Ingelheim International
GmbH, Eli Lilly and Company (NYSE: LLY) and Spectrum Pharmaceuticals, Inc.
(NASDAQ: SPPI). GPC Biotech AG is headquartered in Martinsried/Munich (Germany).
The Company’s wholly owned U.S. subsidiary has research sites in Waltham,
Massachusetts and Princeton, New Jersey. For additional information, please
visit the Company’s Web site at www.gpc-biotech.com.
The economic projections and forward-looking statements contained in this
document relate to future facts. Such projections and forward-looking statements
are subject to risks which cannot be foreseen and which are beyond the control
of GPC Biotech AG. GPC Biotech AG is therefore not in a position to make any
representation as to the accuracy of economic projections and forward-looking
statements or their impact on the financial situation of GPC Biotech AG or the
market in the shares of GPC Biotech AG.
For further information, please contact:
GPC Biotech AG
Fraunhoferstr. 20
82152 Martinsried/Munich, Germany
Phone/Fax: +49 (0)89 8565-2600/-2610
info@gpc-biotech.com
Martin Braendle (ext. 2693)
Manager, Investor Relations & Corporate Communications
martin.braendle@gpc-biotech.com
In the U.S.:
Laurie Doyle
Senior Manager, Investor Relations & Corporate Communications
Phone: +1 781 890 9007 (ext. 267)
Fax: +1 781 890 9005
laurie.doyle@gpc-biotech.com
——————————————————————————–
WKN: 585150; ISIN: DE0005851505; Index: TecDAX, NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart
281827 Nov 03
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found